The median effective dose (ED50) of intravenous oxycodone depending on sex and age for attenuation of intubation-related hemodynamic responses

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002491

Enrollment

240

Registered

2017-10-12

Start date

2018-04-09

Completion date

Unknown

Last updated

2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : All patients will be allocated to one of 6 groups according to sex and age

1) male between 20 to 40 year old (group YM), 2) male between 41 to 65 year old (group OM), 3) female between 20 to 40 year old (group YF), 4) female between 41 to 65 year old (group OF), 5) male

if a patient shows below 20 % changes of these hemodynamics, it is regarded as ‘no response’. If a patient has ‘response’, dose of intravenous oxycodone for subsequent patient is increased by 0.01 mg/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are scheduled to undergo elective surgery under general anesthesia required endotracheal intubation. Patients, aged between 20 to 80 years old, who were American Society of Anesthesiologists physical status I or II.

Exclusion criteria

Exclusion criteria: A. patients with refusal B. patients with acute respiratory distress syndrome, cor pulmonae, acute asthma or other obstructive lung disease C. cardiac arrhythmia D. severe decreased renal function (creatine clearance < 10 mL/min) E. moderate or severe hepatic failure F. patients with brain tumor, impaired mental state, increased intracranial pressure G. patients above 65 years old who can not agree to attend this study with voluntary participation H. recent monoamine oxidase inhibitor (MAOI) taken patients I. patients with complications on opioids or chronic medication J. above 15 second of intubation time. K. other participant in vulnerable environment except elderly patients

Design outcomes

Primary

Measure	Time frame
median effective dose (ED50) of intravenous oxycodone, which can attenuate or prevent 50% of hemodynamic changes by laryngoscopy and tracheal intubation.;95% effective dose (ED95) of intravenous oxycodone, which can attenuate or prevent 95% (ED95) of hemodynamic changes by laryngoscopy and tracheal intubation.	—

Secondary

Measure	Time frame
Hemodynamic change [arterial blood pressure (systolic, diastolic, mean) and heart rate]	—

Countries

Korea, Republic of

Contacts

Public ContactSANG HUN KIM

Chosun University Hospital

drshkim4187@yahoo.co.kr+82-62-220-3223

Outcome results